ArticleJournal of medical cases2026
Challenges of Hepatitis B Virus Reactivation and CD19 Testing Following Tafasitamab Plus Lenalidomide for Relapsed Diffuse Large B-Cell Lymphoma.
Article in Journal of medical cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outcomes of transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are generally poor but much improved by novel targeted therapies and immunotherapies. Tafasitamab plus lenalidomide is an approved regimen for patients with R/R DLBCL. Nonetheless, the clinical data regarding Asian populations and hepatitis B virus (HBV) carriers are lacking in both the pivotal L-MIND and real-world studies. We present an 81-year-old HBV carrier with relapsed DLBCL, who achieved and continued a complete metabolic response (CMR) during 1.5 years of tafasitamab plus lenalidomide as second-line therapy. Notably, an episode of HBV reactivation occurred after four cycles of tafasitamab plus lenalidomide, which was early detected and successfully managed with preemptive nucleotide analogues. Interestingly, CD19 was not detectable by flow cytometry after 10 cycles of treatment despite continuous control of the disease. CD19 expression may be diminished by exams using a tafasitamab-competitive-binding clone. This case highlights not only the concern of HBV reactivation, but also the diagnostic challenge due to CD19 epitope masking following tafasitamab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.